Status:
RECRUITING
First-in-Human Single and Multiple Dose of HL-400
Lead Sponsor:
Highlightll Pharmaceutical (USA) LLC
Conditions:
Parkinson Disease
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics of HL-400 (a NLRP3 inhibitor) following oral si...
Detailed Description
This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics of HL-400 following oral single and multiple as...
Eligibility Criteria
Inclusion
- Are capable of giving written informed consent and complying with study procedures, schedule, requirements, and restrictions.
- Are between the ages of 18 and 65 years, inclusive, at screening.
- Female subjects have a negative serum hCG pregnancy test result at screening andDay （-1）, agree to refrain from ova donation for at least 3 months after the last dose, and willingness to comply with protocol-specified contraceptive methods.
- Male subjects with female partners of reproductive potential must agree to practice abstinence or to use a condom (male subject) plus an additional barrier method (female partner) of contraception for the duration of the study and for at least 3 months after last dosing; must also agree to refrain from sperm donation for at least 3 months after the last dose.
- Considered healthy by the Investigator, based on subject's reported medical history, full physical examination, clinical laboratory tests, 12-lead ECG, and vital signs.
- Non-smoker for at least 6 months prior to screening.
- Body mass index (BMI) of 18.0 to 32.0 kg/m2 inclusive and body weight not less than 50 kg.
Exclusion
- Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug hypersensitivity as determined by the Investigator.
- Pregnant (as determined by pregnancy test result) or breastfeeding women.
- History of chronic diarrhea, malabsorption, unexplained weight loss, food allergies or intolerance.
- Positive blood screen for human immunodeficiency virus (HIV 1/2), hepatitis B surface antigen (HBsAg), or hepatitis C antibody.
- A positive screen for alcohol or drugs of abuse at screening or Day -1.
- An unwillingness or inability to comply with food and beverage restrictions during study participation.
- Volunteers who have participated in any investigational drug or device study within past 3 months prior to dosing.
- Any condition or finding that in the Investigators opinion would put the subject or study conduct at risk if the subject were to participate in the study.
Key Trial Info
Start Date :
April 25 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 27 2026
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT06997484
Start Date
April 25 2025
End Date
February 27 2026
Last Update
May 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pharmaron CPC, Inc.
Baltimore, Maryland, United States, 21201